Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pending Biosimilars

Executive Summary

Biosimilar applications using the 351(k) pathway under review at US FDA. Updated upon new submissions.

Advertisement

Related Content

Neulasta Biosimilar From Coherus Needs Better Immunogenicity Assay After Stumble At US FDA
Pfizer Excludes EU Biosimilar Experience From US Epoetin Application
Biosimilar Advisory Committees Getting Smoother, Even As Worries Stay The Same
Hospira's Epogen Biosimilar Appears Poised For Quick Advisory Cmte. OK
Biosimilars: Next User Fee Cycle Will Be Judged On US FDA's Approvals, Rep. Burgess Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS120038

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel